Track topics on Twitter Track topics that are important to you
The collaboration leverages Abpro’s proprietary DiversImmuneTM antibody discovery platform. Under the terms of the agreement, Abpro is eligible to receive up to $4 billion, ...
Abpro and Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (NJCTTQ; a division of Chia Tai Tianqing Pharmaceutical Group Co. Ltd.) will work together to discover and develop bispecific antibodies for...
NJCTTQ, a Nanjing pharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts. NJCTTQ will have China and Thai rights to multiple immu...
Abpro and NJCTTQ enter $4bn agreement to develop bispecific antibody therapies for immuno-oncology and extend its global reach.
Abpro have streamlined all aspects of the process to create a state-of-the-art gene-to-antibody platform that allows rapid generation of antibodies against previously difficult targets. Applications i...
Abpro, based in Woburn, Mass., inked a deal worth up to $4 billion with China-based Nanjing Chia Tai Tianqing Pharmaceutical Company, known as NJCTTQ, a global pharmaceutical company.
Abpro eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royaltiesCollaboration to result in multiple new immuno-oncology bispecif...
We have published hundreds of Abpro news stories on BioPortfolio along with dozens of Abpro Clinical Trials and PubMed Articles about Abpro for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Abpro Companies in our database. You can also find out about relevant Abpro Drugs and Medications on this site too.